{ "run": { "id": "cmnr156ah06afp6582wr0vo8b", "region": "US", "assetId": "cmnr156a306a9p658h6zviajv", "ticker": "STE", "snapshotId": "cmnr156a906abp6585chlg3vc", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:51.639Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr156a906abp6585chlg3vc", "assetId": "cmnr156a306a9p658h6zviajv", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 224.27, "price": 225.03, "dayLow": 222.475, "volume": 469673, "dayHigh": 225.345, "currency": "USD", "prevClose": 219.22, "week52Low": 204.9, "week52High": 269.44 }, "fundamentals": { "pe": 36.3221153846154, "beta": 0.798335937436449, "epsTTM": 6.24, "fcfTTM": 480508000, "growth": { "epsYoy": 0.6292428198433421, "revenueYoy": -0.7259463523774548 }, "sector": "Orthopedic, Prosthetic & Surgical Appliances & Supplies", "margins": { "net": 0.1289266140890255, "gross": 0.4381098783585082, "operating": 0.182595909637749 }, "website": "http://steris.com", "industry": "Medical devices", "pegRatio": 0.577235277689116, "ebitdaTTM": 1450728000, "forwardPe": 22.1554252199413, "marketCap": 23874000000, "totalCash": 423700000, "totalDebt": 1898400000, "debtEquity": 0.309491996931886, "quickRatio": 1.533448986230077, "revenueTTM": 1496200000, "companyName": "STERIS plc", "priceToBook": 3.37709256098735, "currentRatio": 2.478802992518703, "dividendYield": 0.00984131976853708, "returnOnAssets": 0.01821288970296656, "returnOnEquity": 0.0930794037318626, "analystOpinions": null, "businessSummary": "Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.", "enterpriseValue": 24214023750, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 18179, "sharesOutstanding": 98075025, "enterpriseToEbitda": 16.69094671778583, "analystTargetMedian": null, "enterpriseToRevenue": 16.18368115893597, "operatingCashflowTTM": 1006000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:51.634Z" }, "results": [ { "id": "cmnr156ak06amp658gcz853mr", "runId": "cmnr156ah06afp6582wr0vo8b", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-3.7-ai-equity-research\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"STE\",\"currency\":\"USD\",\"current_price\":225.03,\"target_price_6m\":238.0,\"target_price_12m\":252.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Attractive PEG of 0.58 signals undervaluation relative to earnings growth trajectory\",\"Post-divestiture streamlined portfolio should improve margins and capital allocation focus\",\"Forward PE of 22x reasonable for defensive medical-device compounder with low beta\",\"Strong balance sheet with 2.5x current ratio and low 0.31 debt-to-equity supports durability\",\"Stock trades 16% below 52-week high creating a favorable entry point\"],\"key_drivers\":[{\"driver\":\"Post-divestiture earnings normalization driving forward EPS step-up\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Hospital procedure volume recovery supporting core sterilization demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion toward 20%+ from current 18.3%\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Recurring revenue from consumables and service contracts\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Strong FCF generation enabling capital returns and bolt-on M&A\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Macro uncertainty could delay hospital capital equipment spending\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Elevated TTM PE of 36x may limit near-term multiple expansion\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta limits upside capture in broad market rallies\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Hospital capital expenditure deferrals in recessionary environment\",\"Integration or normalization risks following major divestiture\",\"Currency headwinds from international operations given Irish domicile\",\"Competitive pressure in sterilization and surgical products segments\",\"Potential tariff or trade policy impact on medical device supply chains\"],\"assumptions\":{\"revenue_cagr_3y\":0.07,\"ebit_margin_target\":0.20,\"wacc\":0.085,\"terminal_multiple\":23.0},\"scenarios\":{\"bear\":{\"target_price\":198.0,\"prob\":0.20,\"notes\":\"Hospital capex cuts and macro slowdown compress multiples to 19-20x forward earnings.\"},\"base\":{\"target_price\":252.0,\"prob\":0.55,\"notes\":\"Steady execution on ~$10+ forward EPS at 24x forward PE with modest margin expansion.\"},\"bull\":{\"target_price\":285.0,\"prob\":0.25,\"notes\":\"Accelerating procedure volumes and margin expansion drive re-rating toward 27x forward earnings.\"}},\"method_notes\":\"Earnings-power valuation anchored on forward PE (22.16x from snapshot) and implied forward EPS of ~$10.16. Applied modest multiple expansion in base case given low PEG (0.58) and defensive profile. Revenue TTM of $1.5B appears post-divestiture; valuation relies primarily on earnings metrics. 12M target implies ~12% return supporting BUY. Scenario-weighted expected value ~$248. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "claude-3.7-ai-equity-research", "risks": [ "Hospital capital expenditure deferrals in recessionary environment", "Integration or normalization risks following major divestiture", "Currency headwinds from international operations given Irish domicile", "Competitive pressure in sterilization and surgical products segments", "Potential tariff or trade policy impact on medical device supply chains" ], "ticker": "STE", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady execution on ~$10+ forward EPS at 24x forward PE with modest margin expansion.", "target_price": 252 }, "bear": { "prob": 0.2, "notes": "Hospital capex cuts and macro slowdown compress multiples to 19-20x forward earnings.", "target_price": 198 }, "bull": { "prob": 0.25, "notes": "Accelerating procedure volumes and margin expansion drive re-rating toward 27x forward earnings.", "target_price": 285 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.07, "terminal_multiple": 23, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Post-divestiture earnings normalization driving forward EPS step-up", "impact": "HIGH", "direction": "POS" }, { "driver": "Hospital procedure volume recovery supporting core sterilization demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion toward 20%+ from current 18.3%", "impact": "MED", "direction": "POS" }, { "driver": "Recurring revenue from consumables and service contracts", "impact": "MED", "direction": "POS" }, { "driver": "Strong FCF generation enabling capital returns and bolt-on M&A", "impact": "MED", "direction": "POS" }, { "driver": "Macro uncertainty could delay hospital capital equipment spending", "impact": "MED", "direction": "NEG" }, { "driver": "Elevated TTM PE of 36x may limit near-term multiple expansion", "impact": "MED", "direction": "NEG" }, { "driver": "Low beta limits upside capture in broad market rallies", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Earnings-power valuation anchored on forward PE (22.16x from snapshot) and implied forward EPS of ~$10.16. Applied modest multiple expansion in base case given low PEG (0.58) and defensive profile. Revenue TTM of $1.5B appears post-divestiture; valuation relies primarily on earnings metrics. 12M target implies ~12% return supporting BUY. Scenario-weighted expected value ~$248. Not investment advice.", "current_price": 225.03, "recommendation": "BUY", "thesis_bullets": [ "Attractive PEG of 0.58 signals undervaluation relative to earnings growth trajectory", "Post-divestiture streamlined portfolio should improve margins and capital allocation focus", "Forward PE of 22x reasonable for defensive medical-device compounder with low beta", "Strong balance sheet with 2.5x current ratio and low 0.31 debt-to-equity supports durability", "Stock trades 16% below 52-week high creating a favorable entry point" ], "target_price_6m": 238, "target_price_12m": 252 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 46234, "createdAt": "2026-04-09T05:21:51.639Z", "usage": { "inputTokens": 3612, "outputTokens": 1897, "costUsd": 0.065485 } }, { "id": "cmnr156ak06app658lponf894", "runId": "cmnr156ah06afp6582wr0vo8b", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Analyst\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"STE\",\n \"currency\": \"USD\",\n \"current_price\": 225.03,\n \"target_price_6m\": 235.0,\n \"target_price_12m\": 246.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"EPS growth strong but revenue decline a concern.\",\n \"Margins improving, supporting future profitability.\",\n \"Valuation reasonable based on forward earnings.\",\n \"Strong cash flow enables shareholder returns.\",\n \"Industry tailwinds from healthcare spending growth.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"EPS Growth Rate\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Revenue Stabilization Trend\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Operating Margin Expansion\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt to Equity Ratio\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Market Leadership in Sterilization\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory Compliance Costs\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competitive Pressure in Medical Devices\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic Sensitivity\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Revenue volatility persists\", \"Increased regulatory scrutiny\", \"Supply chain disruptions\", \"Execution risks on growth\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.20,\n \"wacc\": 0.08,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 220.0, \"prob\": 0.2, \"notes\": \"Weaker than expected growth and margin pressure.\" },\n \"base\": { \"target_price\": 246.0, \"prob\": 0.6, \"notes\": \"Base assumptions of stabilization and moderate growth hold.\" },\n \"bull\": { \"target_price\": 270.0, \"prob\": 0.2, \"notes\": \"Strong execution and market share gains drive outperformance.\" }\n },\n \"method_notes\": \"Valuation based on forward PE multiple with EPS growth assumptions. BUY due to ~9% upside; mixed evidence limits confidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Analyst", "risks": [ "Revenue volatility persists", "Increased regulatory scrutiny", "Supply chain disruptions", "Execution risks on growth" ], "ticker": "STE", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Base assumptions of stabilization and moderate growth hold.", "target_price": 246 }, "bear": { "prob": 0.2, "notes": "Weaker than expected growth and margin pressure.", "target_price": 220 }, "bull": { "prob": 0.2, "notes": "Strong execution and market share gains drive outperformance.", "target_price": 270 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.03, "terminal_multiple": 16, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "EPS Growth Rate", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue Stabilization Trend", "impact": "MED", "direction": "POS" }, { "driver": "Operating Margin Expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt to Equity Ratio", "impact": "LOW", "direction": "POS" }, { "driver": "Market Leadership in Sterilization", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory Compliance Costs", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive Pressure in Medical Devices", "impact": "MED", "direction": "NEG" }, { "driver": "Economic Sensitivity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on forward PE multiple with EPS growth assumptions. BUY due to ~9% upside; mixed evidence limits confidence. Not investment advice.", "current_price": 225.03, "recommendation": "BUY", "thesis_bullets": [ "EPS growth strong but revenue decline a concern.", "Margins improving, supporting future profitability.", "Valuation reasonable based on forward earnings.", "Strong cash flow enables shareholder returns.", "Industry tailwinds from healthcare spending growth." ], "target_price_6m": 235, "target_price_12m": 246 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 379, "createdAt": "2026-04-09T05:21:51.639Z", "usage": { "inputTokens": 2111, "outputTokens": 3270, "costUsd": 0.001964 } }, { "id": "cmnr156ak06anp6581aobnpwj", "runId": "cmnr156ah06afp6582wr0vo8b", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"STE\",\n \"currency\": \"USD\",\n \"current_price\": 225.03,\n \"target_price_6m\": 235.00,\n \"target_price_12m\": 245.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.70,\n \"thesis_bullets\": [\n \"Forward P/E of 22x is attractive relative to historical medtech averages.\",\n \"Strong EPS growth (+62% YoY) reflects successful cost optimization and divestitures.\",\n \"High recurring revenue from consumables and services provides downside protection.\",\n \"Hospital capital expenditure environment remains a near-term risk for equipment sales.\",\n \"Solid balance sheet with manageable debt supports future tuck-in acquisitions.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Hospital Capex Budgets\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Consumables Volume Growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Divestiture of Non-Core Assets\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Raw Material Inflation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Healthcare Labor Shortages\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Tuck-in M&A Integration\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged constraints on hospital capital expenditures delaying equipment upgrades.\",\n \"Supply chain disruptions impacting raw material availability and costs.\",\n \"Foreign exchange headwinds due to international exposure.\",\n \"Integration risks associated with recent and future acquisitions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.075,\n \"terminal_multiple\": 20.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 190.00,\n \"prob\": 0.20,\n \"notes\": \"Hospital capex freezes and margin compression lead to multiple contraction.\"\n },\n \"base\": {\n \"target_price\": 245.00,\n \"prob\": 0.60,\n \"notes\": \"Steady consumables growth and realized cost synergies drive earnings expansion.\"\n },\n \"bull\": {\n \"target_price\": 275.00,\n \"prob\": 0.20,\n \"notes\": \"Accelerated equipment replacement cycle and accretive M&A boost valuation.\"\n }\n },\n \"method_notes\": \"Valuation based on 24x forward P/E and DCF (7.5% WACC, 20x terminal EV/EBITDA). Snapshot revenue anomaly implies divestiture impact, but forward EPS supports upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation", "risks": [ "Prolonged constraints on hospital capital expenditures delaying equipment upgrades.", "Supply chain disruptions impacting raw material availability and costs.", "Foreign exchange headwinds due to international exposure.", "Integration risks associated with recent and future acquisitions." ], "ticker": "STE", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady consumables growth and realized cost synergies drive earnings expansion.", "target_price": 245 }, "bear": { "prob": 0.2, "notes": "Hospital capex freezes and margin compression lead to multiple contraction.", "target_price": 190 }, "bull": { "prob": 0.2, "notes": "Accelerated equipment replacement cycle and accretive M&A boost valuation.", "target_price": 275 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.05, "terminal_multiple": 20, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Hospital Capex Budgets", "impact": "HIGH", "direction": "POS" }, { "driver": "Consumables Volume Growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Divestiture of Non-Core Assets", "impact": "MED", "direction": "POS" }, { "driver": "Raw Material Inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Healthcare Labor Shortages", "impact": "MED", "direction": "NEG" }, { "driver": "Tuck-in M&A Integration", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on 24x forward P/E and DCF (7.5% WACC, 20x terminal EV/EBITDA). Snapshot revenue anomaly implies divestiture impact, but forward EPS supports upside. Not investment advice.", "current_price": 225.03, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 22x is attractive relative to historical medtech averages.", "Strong EPS growth (+62% YoY) reflects successful cost optimization and divestitures.", "High recurring revenue from consumables and services provides downside protection.", "Hospital capital expenditure environment remains a near-term risk for equipment sales.", "Solid balance sheet with manageable debt supports future tuck-in acquisitions." ], "target_price_6m": 235, "target_price_12m": 245 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24293, "createdAt": "2026-04-09T05:21:51.639Z", "usage": { "inputTokens": 2483, "outputTokens": 810, "costUsd": 0.014686 } }, { "id": "cmnr156ak06alp658qxhyqwgp", "runId": "cmnr156ah06afp6582wr0vo8b", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"STE\",\"currency\":\"USD\",\"current_price\":225.03,\"target_price_6m\":217,\"target_price_12m\":233,\"recommendation\":\"HOLD\",\"confidence\":0.61,\"thesis_bullets\":[\"Recurring sterile services support resilient healthcare demand.\",\"Procedure recovery and replacement cycles should aid steady growth.\",\"Pricing, mix, and productivity can lift margins further.\",\"Starting valuation already prices in much of the improvement.\",\"Conflicting snapshot fundamentals reduce conviction in upside.\"],\"key_drivers\":[{\"driver\":\"Procedure volume recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Applied Sterilization growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Hospital equipment replacement\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing over inflation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Rich starting valuation\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory quality compliance\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Acquisition integration execution\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Hospital capex delays\",\"Regulatory warning letters or recalls\",\"Procedure softness\",\"FX translation headwinds\",\"Litigation or product liability\"],\"assumptions\":{\"revenue_cagr_3y\":7,\"ebit_margin_target\":21,\"wacc\":8.2,\"terminal_multiple\":15.5},\"scenarios\":{\"bear\":{\"target_price\":195,\"prob\":0.25,\"notes\":\"Capex weakens and margins stall, compressing multiples.\"},\"base\":{\"target_price\":233,\"prob\":0.5,\"notes\":\"Steady procedure demand and modest margin expansion support fair value.\"},\"bull\":{\"target_price\":262,\"prob\":0.25,\"notes\":\"Faster services growth and stronger productivity drive upside.\"}},\"method_notes\":\"12M target uses blended forward earnings and EV/EBITDA with normalized margin assumptions. Snapshot quote fields were kept exactly; snapshot revenue and revenueYoY appear internally inconsistent versus EBITDA, so confidence is moderate. No sell-side price targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "OpenAI o3", "risks": [ "Hospital capex delays", "Regulatory warning letters or recalls", "Procedure softness", "FX translation headwinds", "Litigation or product liability" ], "ticker": "STE", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady procedure demand and modest margin expansion support fair value.", "target_price": 233 }, "bear": { "prob": 0.25, "notes": "Capex weakens and margins stall, compressing multiples.", "target_price": 195 }, "bull": { "prob": 0.25, "notes": "Faster services growth and stronger productivity drive upside.", "target_price": 262 } }, "confidence": 0.61, "assumptions": { "wacc": 8.2, "revenue_cagr_3y": 7, "terminal_multiple": 15.5, "ebit_margin_target": 21 }, "key_drivers": [ { "driver": "Procedure volume recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Applied Sterilization growth", "impact": "MED", "direction": "POS" }, { "driver": "Hospital equipment replacement", "impact": "MED", "direction": "POS" }, { "driver": "Pricing over inflation", "impact": "MED", "direction": "POS" }, { "driver": "Margin normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Rich starting valuation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory quality compliance", "impact": "HIGH", "direction": "NEG" }, { "driver": "Acquisition integration execution", "impact": "MED", "direction": "NEG" } ], "method_notes": "12M target uses blended forward earnings and EV/EBITDA with normalized margin assumptions. Snapshot quote fields were kept exactly; snapshot revenue and revenueYoY appear internally inconsistent versus EBITDA, so confidence is moderate. No sell-side price targets used; not investment advice.", "current_price": 225.03, "recommendation": "HOLD", "thesis_bullets": [ "Recurring sterile services support resilient healthcare demand.", "Procedure recovery and replacement cycles should aid steady growth.", "Pricing, mix, and productivity can lift margins further.", "Starting valuation already prices in much of the improvement.", "Conflicting snapshot fundamentals reduce conviction in upside." ], "target_price_6m": 217, "target_price_12m": 233 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_096f4b91e29d1ff70069d75d7cb5d081978a2a27019b6c3a8b", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 41255, "createdAt": "2026-04-09T05:21:51.639Z", "usage": { "inputTokens": 2384, "outputTokens": 1975, "costUsd": 0.031822 } }, { "id": "cmnr156ak06aop658lqwlx2v7", "runId": "cmnr156ah06afp6582wr0vo8b", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"STE\",\n \"currency\": \"USD\",\n \"current_price\": 225.03,\n \"target_price_6m\": 235,\n \"target_price_12m\": 245,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Strong sterilization demand supports stable healthcare revenue\",\n \"Margin gains offset recent revenue softness and EPS growth\",\n \"Forward PE of 22 reasonable for mid-single digit growth\",\n \"Robust FCF funds dividends and potential bolt-on M&A\",\n \"Hospital budgets and regulatory hurdles pose execution risks\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Hospital capital expenditure\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Infection prevention demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New product approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Margin expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medtech competition\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Acquisition integration\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Healthcare policy changes\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Interest rate environment\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged hospital budget constraints\",\n \"Regulatory delays on new devices\",\n \"Increased competition in sterilization\",\n \"Supply chain cost inflation\",\n \"FX volatility on international sales\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.085,\n \"terminal_multiple\": 17\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 195,\n \"prob\": 0.25,\n \"notes\": \"Hospital spending cuts and integration misses hit growth.\"\n },\n \"base\": {\n \"target_price\": 245,\n \"prob\": 0.5,\n \"notes\": \"Steady demand and margin gains deliver mid-single digit growth.\"\n },\n \"bull\": {\n \"target_price\": 285,\n \"prob\": 0.25,\n \"notes\": \"Accelerated adoption of new tech and accretive M&A.\"\n }\n },\n \"method_notes\": \"DCF valuation using 8% 3Y revenue CAGR, 20% EBIT margin target, 8.5% WACC and 17x terminal EV/EBITDA. 12M target implies ~9% upside consistent with BUY. Snapshot fundamentals used as baseline. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "Prolonged hospital budget constraints", "Regulatory delays on new devices", "Increased competition in sterilization", "Supply chain cost inflation", "FX volatility on international sales" ], "ticker": "STE", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady demand and margin gains deliver mid-single digit growth.", "target_price": 245 }, "bear": { "prob": 0.25, "notes": "Hospital spending cuts and integration misses hit growth.", "target_price": 195 }, "bull": { "prob": 0.25, "notes": "Accelerated adoption of new tech and accretive M&A.", "target_price": 285 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.08, "terminal_multiple": 17, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Hospital capital expenditure", "impact": "HIGH", "direction": "POS" }, { "driver": "Infection prevention demand", "impact": "HIGH", "direction": "POS" }, { "driver": "New product approvals", "impact": "MED", "direction": "POS" }, { "driver": "Margin expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Medtech competition", "impact": "MED", "direction": "NEG" }, { "driver": "Acquisition integration", "impact": "MED", "direction": "NEG" }, { "driver": "Healthcare policy changes", "impact": "MED", "direction": "NEG" }, { "driver": "Interest rate environment", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF valuation using 8% 3Y revenue CAGR, 20% EBIT margin target, 8.5% WACC and 17x terminal EV/EBITDA. 12M target implies ~9% upside consistent with BUY. Snapshot fundamentals used as baseline. Not investment advice.", "current_price": 225.03, "recommendation": "BUY", "thesis_bullets": [ "Strong sterilization demand supports stable healthcare revenue", "Margin gains offset recent revenue softness and EPS growth", "Forward PE of 22 reasonable for mid-single digit growth", "Robust FCF funds dividends and potential bolt-on M&A", "Hospital budgets and regulatory hurdles pose execution risks" ], "target_price_6m": 235, "target_price_12m": 245 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "a32760e0-d981-93d3-bff5-a24abb519a8c", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 17339, "createdAt": "2026-04-09T05:21:51.639Z", "usage": { "inputTokens": 2723, "outputTokens": 2758, "costUsd": 0.049539 } } ] } }